发布求助
文献互助 智能选刊 最新文献

Australian Prescriber最新文献

筛选
英文 中文
Pharmacological management of polycystic ovary syndrome. 多囊卵巢综合征的药物治疗。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.030
Carolyn Ee, Chau Thien Tay
{"title":"Pharmacological management of polycystic ovary syndrome.","authors":"Carolyn Ee, Chau Thien Tay","doi":"10.18773/austprescr.2024.030","DOIUrl":"10.18773/austprescr.2024.030","url":null,"abstract":"<p><p>Polycystic ovary syndrome is a common and frequently undiagnosed female endocrine disorder that is associated with diverse symptoms and features, and an increased risk of long-term chronic diseases such as type 2 diabetes and cardiovascular disease. Pharmacotherapy for polycystic ovary syndrome should be directed at the key concerns of the individual patient. The combined oral contraceptive pill or metformin may be prescribed for irregular periods. The combined oral contraceptive pill is preferred over antiandrogens for treatment of hirsutism and acne. Metformin is of benefit for reducing excess body weight and improving hormonal and metabolic outcomes in those with high metabolic risk (e.g. body mass index greater than 25 kg/m<sup>2</sup>). Inositol appears to have limited benefits for metabolic outcomes, although it is associated with fewer adverse effects than metformin. Modification of lifestyle factors is important as part of a holistic approach to managing polycystic ovary syndrome. Anti-obesity drugs may be considered for weight management in addition to lifestyle interventions.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"109-112"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368538/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127480","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Utility of common investigations for suspected inflammatory arthritis in adults. 成人疑似炎症性关节炎常见检查的实用性。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.035
Nicola Cook, Rachelle Buchbinder
{"title":"Utility of common investigations for suspected inflammatory arthritis in adults.","authors":"Nicola Cook, Rachelle Buchbinder","doi":"10.18773/austprescr.2024.035","DOIUrl":"10.18773/austprescr.2024.035","url":null,"abstract":"<p><p>Inflammatory arthritis may be the principal feature or one component of an inflammatory rheumatological disease. It is a clinical diagnosis, principally made based on the patient's history and examination. Specific investigations, such as rheumatoid factor and human leucocyte antigen B27 gene, may support the diagnosis in the context of a suggestive clinical presentation, but a diagnosis cannot be made based on these tests alone because positive results may also be seen in healthy individuals. To reduce the likelihood of false positive results, laboratory and radiological investigations should be tailored to the suspected diagnosis based on pretest probability. While musculoskeletal symptoms are a common presentation in general practice, specific features that increase suspicion of an inflammatory arthritis include prolonged morning stiffness (more than 1 hour) that is improved by exercise or movement. A broad 'rheumatological panel' increases the likelihood of false positive results and should be avoided to prevent unnecessary further investigations and treatment, and unwarranted anxiety in both the patient and the doctor.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"119-124"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368532/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127484","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Difelikefalin for pruritus associated with chronic kidney disease. 治疗与慢性肾病有关的瘙痒症的地夫立克萘林
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.032
{"title":"Difelikefalin for pruritus associated with chronic kidney disease.","authors":"","doi":"10.18773/austprescr.2024.032","DOIUrl":"10.18773/austprescr.2024.032","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"132-133"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368537/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Rimegepant for migraine. 治疗偏头痛的 Rimegepant。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.029
{"title":"Rimegepant for migraine.","authors":"","doi":"10.18773/austprescr.2024.029","DOIUrl":"10.18773/austprescr.2024.029","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"134-135"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368539/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sum of the parts: a cascade of adverse effects. 各部分的总和：一连串的负面影响。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.031
Jane Poon, Fiona Coombes, Ian Coombes
{"title":"Sum of the parts: a cascade of adverse effects.","authors":"Jane Poon, Fiona Coombes, Ian Coombes","doi":"10.18773/austprescr.2024.031","DOIUrl":"10.18773/austprescr.2024.031","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"125-128"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127483","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Achieving safe medication management during transitions of care from hospital: time for a stewardship approach. 在医院护理过渡期间实现安全用药管理：是时候采用管理方法了。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.034
Rohan A Elliott, Manya Angley, Deirdre T Criddle, Fatemeh Emadi, Shania Liu, Jonathan Penm
{"title":"Achieving safe medication management during transitions of care from hospital: time for a stewardship approach.","authors":"Rohan A Elliott, Manya Angley, Deirdre T Criddle, Fatemeh Emadi, Shania Liu, Jonathan Penm","doi":"10.18773/austprescr.2024.034","DOIUrl":"10.18773/austprescr.2024.034","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"106-108"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368533/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127476","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Management of occupational exposure to blood and body fluids in primary care. 初级保健中对职业性接触血液和体液的管理。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.037
Anna Pierce
{"title":"Management of occupational exposure to blood and body fluids in primary care.","authors":"Anna Pierce","doi":"10.18773/austprescr.2024.037","DOIUrl":"10.18773/austprescr.2024.037","url":null,"abstract":"<p><p>Primary care workplaces where occupational exposure to blood and body fluids may occur should have policies and procedures in place to manage such incidents. All healthcare workers should be immunised against hepatitis B and ideally should have documentation of their antibody response to vaccination. Knowledge of hepatitis B immune status helps streamline the response to any exposure. Most occupational exposures carry a low risk of transmission of bloodborne viruses, and management can often be undertaken in general practice. Urgent risk assessment and management is crucial. If postexposure prophylaxis for hepatitis B or HIV is required, the earlier it is given, the more likely it is to be effective. Two-drug HIV postexposure prophylaxis is now more accessible because generic formulations of the drug combination are available, and general practitioners can prescribe this on a private prescription.</p>","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"113-118"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368531/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127478","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
QUM revisited. 重温 QUM。
IF 3.4
Australian Prescriber Pub Date : 2024-08-01 DOI: 10.18773/austprescr.2024.036
John Dowden
{"title":"QUM revisited.","authors":"John Dowden","doi":"10.18773/austprescr.2024.036","DOIUrl":"10.18773/austprescr.2024.036","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 4","pages":"131"},"PeriodicalIF":3.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11368536/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142127481","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Additional preconception considerations for patients with diabetes. 糖尿病患者孕前的其他注意事项。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.022
{"title":"Additional preconception considerations for patients with diabetes.","authors":"","doi":"10.18773/austprescr.2024.022","DOIUrl":"10.18773/austprescr.2024.022","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"95-96"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216911/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Medicines Repurposing Program - supporting new uses for existing medicines. 药品再利用计划--支持现有药品的新用途。
IF 3.4
Australian Prescriber Pub Date : 2024-06-01 DOI: 10.18773/austprescr.2024.025
{"title":"Medicines Repurposing Program - supporting new uses for existing medicines.","authors":"","doi":"10.18773/austprescr.2024.025","DOIUrl":"10.18773/austprescr.2024.025","url":null,"abstract":"","PeriodicalId":55588,"journal":{"name":"Australian Prescriber","volume":"47 3","pages":"97"},"PeriodicalIF":3.4,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11216917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141499736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
首页 上一页 下一页 尾页
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整，为了账户安全，请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们：info@booksci.cn Book学术提供免费学术资源搜索服务，方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号：481959085
Book学术官方微信